Welcome to the Jacoby & Meyers website, please upgrade your Flash Plugin and enable JavaScript.

Pradaxa

Defective drugs disrupt your health and safety when they cause life-altering complications. Like other blood-thinning medications, Pradaxa prevents blood clots at the risk of causing serious complications, including internal bleeding; however, hundreds of Pradaxa users have reported severe, unexpected and uncontrollable bleeding, which could lead to death.

At Jacoby & Meyers, our attorneys can determine if you are entitled to seek damages for severe, unexpected side effects of Pradaxa.

Pradaxa Risks under Investigation

Pradaxa is a blood-thinning medication that the FDA approved in 2010 to prevent blood clots and strokes in people with atrial fibrillation, a condition involving an irregular heartbeat. Pradaxa has been heralded as an alternative to decades-old warfarin, a blood-thinning medication requiring careful monitoring and restrictions on what you can eat while taking it.

About a year after Pradaxa was approved, the drug's maker, Boehringer Ingelheim acknowledged that 260 people worldwide had died because of fatal bleeding linked to Pradaxa. A month later, in December 2011, the FDA began investigating cases of Pradaxa-related bleeding reported to its Adverse Events Reporting System. Pradaxa may be causing excessive internal bleeding beyond what is expected.

Although all anticoagulants carry the risk of bleeding, Boehringer Ingelheim has a responsibility to inform prescribing doctors of the exact nature, likelihood and extent of possible bleeding. A fatality caused by uncontrollable bleeding or other complications of Pradaxa may be a wrongful death if the drug's manufacturer acted negligently and failed to provide complete information about possible risks.

Serious Complications linked to Pradaxa

Pradaxa may be linked to several severe complications, including:

  • Heart attack
  • Kidney failure
  • Hemorrhagic stroke
  • Uncontrollable bleeding
  • Death

Pradaxa may increase the risk of heart attack by 33 percent for people taking the drug for atrial fibrillation, compared to people taking warfarin or enoxaparin for the condition. Researchers at the Cleveland Clinic discovered this increased risk after reviewing data from seven Pradaxa clinical trials involving more than 30,000 patients.

There is some indication that severe bleeding caused by Pradaxa cannot be stopped once it has begun. According to the Journal of Neurosurgery, bleeding caused by Pradaxa is irreversible because there is no drug or other antidote to stop it. Conversely, when warfarin causes internal bleeding, medical professionals are typically able to stop it.

If you are currently taking Pradaxa and have experienced any of the above complications, you may be able to seek compensation for the expense and harm the complication has caused. You should not stop taking Pradaxa without consulting your doctor.

To learn more about Pradaxa litigation, please contact Jacoby & Meyers to schedule a consultation. We have offices nationwide.